4
Changes in Ownership
Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-025116
Chief Accounting Officer sold 697 shares at an average $3.67 ($2,556)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Hagen Brett R · Chief Accounting Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-04-19 | Sale : show line 1 in the form 10b5-1 | −348 | $3.71 | $1,291 | 134,906 | D |
| 2023-04-20 | Sale : show line 2 in the form 10b5-1 | −349 | $3.63 | $1,265 | 134,557 | D |
| Open-market sales · 697 sh · avg $3.67 · $2,556 | ||||||
Loading xslF345X04/doc4.xml…